Duvelisib for CLL/SLL and Follicular Non-Hodgkin Lymphoma.

Publication Title

Blood

Authors

Krish Patel, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USAFollow
Alexey Danilov
John M Pagel, SWEDISH CANCER INSTITUTE.Follow

Document Type

Article

Publication Date

9-25-2019

Abstract

Chronic lymphocytic leukemia (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second generation oral inhibitor of phosphoinositide-3 kinase (PI3K), downstream of the B-cell receptor pathway, approved in the United States for relapsed CLL/SLL and FL. Duvelisib represents a highly active agent and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune mediated toxicities.

Clinical Institute

Cancer

Specialty/Research Institute

Oncology